Plus Therapeutics Enters New Agreement, Terminates Old One
Ticker: PSTV · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $3.3 million, $3.3 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, termination, financial-obligation
TL;DR
PLUS THERAPEUTICS just signed a new deal and ditched an old one, creating new financial obligations.
AI Summary
On May 31, 2024, PLUS THERAPEUTICS, INC. entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. This action also created a direct financial obligation for the registrant. The company was formerly known as CYTORI THERAPEUTICS, INC. and MACROPORE INC.
Why It Matters
This filing indicates a significant shift in the company's contractual obligations, potentially impacting its financial structure and strategic direction.
Risk Assessment
Risk Level: medium — Entering into new agreements and terminating old ones, especially those creating financial obligations, can introduce financial and operational risks.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- CYTORI THERAPEUTICS, INC. (company) — Former Company Name
- MACROPORE INC (company) — Former Company Name
- May 31, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by PLUS THERAPEUTICS, INC. on May 31, 2024?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What were the terms of the material definitive agreement that was terminated by PLUS THERAPEUTICS, INC. on May 31, 2024?
The filing states that a material definitive agreement was terminated, but the specific terms of the terminated agreement are not detailed in the provided text.
What direct financial obligation was created for PLUS THERAPEUTICS, INC. as a result of these agreements?
The filing mentions the creation of a direct financial obligation, but the specific details of this obligation are not disclosed in the provided text.
What is the business address of PLUS THERAPEUTICS, INC.?
The business address of PLUS THERAPEUTICS, INC. is 4200 MARATHON BLVD., SUITE 200, AUSTIN, TX 78756.
When did PLUS THERAPEUTICS, INC. change its name from CYTORI THERAPEUTICS, INC.?
PLUS THERAPEUTICS, INC. changed its name from CYTORI THERAPEUTICS, INC. on July 12, 2005.
Filing Stats: 1,005 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-06-04 17:16:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PSTV The Nasdaq
- $3.3 million — Therapeutics, Inc. (the "Company") drew $3.3 million on its existing margin loan facility (t
- $3.3 m — yment amount that totaled approximately $3.3 million, which included both the balance
Filing Documents
- d840235d8k.htm (8-K) — 30KB
- d840235dex101.htm (EX-10.1) — 94KB
- d840235dex102.htm (EX-10.2) — 52KB
- d840235dex103.htm (EX-10.3) — 28KB
- g840235dsp0013.jpg (GRAPHIC) — 3KB
- g840235dsp011.jpg (GRAPHIC) — 1KB
- g840235dsp011a.jpg (GRAPHIC) — 1KB
- g840235dsp011b.jpg (GRAPHIC) — 5KB
- 0001193125-24-154380.txt ( ) — 374KB
- pstv-20240531.xsd (EX-101.SCH) — 3KB
- pstv-20240531_lab.xml (EX-101.LAB) — 18KB
- pstv-20240531_pre.xml (EX-101.PRE) — 11KB
- d840235d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 10.1 Lending Agreement, dated April 5, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC 10.2 Loan Interest Rate Form, dated May 24, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC 10.3 Extension of Credit, dated May 29, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: June 4, 2024 By: /s/ Andrew Sims Name: Andrew Sims Title: Chief Financial Officer